Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?

Abstract

To the Editor: We read with interest the paper by Gillmore et al. [1] regarding the impact of the European Association for the Study of the Liver (EASL) and modified Response Evaluation Criteria In Solid Tumors (mRECIST) on survival in hepatocellular carcinoma (HCC) patients treated with transarterial embolization. The authors compared RECIST1.1, EASL and… (More)
DOI: 10.1016/j.jhep.2012.01.016

Topics

1 Figure or Table